Shares of Ralliant Corporation (NYSE:RAL – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twelve research firms that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have given a buy rating to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $61.90.
RAL has been the subject of a number of analyst reports. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Citigroup increased their price target on Ralliant from $51.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d)” rating on shares of Ralliant in a research report on Monday, May 4th. Barclays increased their price target on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research report on Wednesday. Finally, Vertical Research raised Ralliant from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Friday, February 6th.
View Our Latest Report on Ralliant
Ralliant Trading Up 0.1%
Ralliant (NYSE:RAL – Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. The business had revenue of $534.60 million during the quarter. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.Ralliant’s quarterly revenue was up 11.0% on a year-over-year basis. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. On average, analysts predict that Ralliant will post 2.63 EPS for the current fiscal year.
Ralliant Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 23rd. Investors of record on Monday, June 8th will be given a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, June 8th. Ralliant’s dividend payout ratio is presently -1.83%.
Insider Transactions at Ralliant
In other news, SVP Karen M. Bick sold 5,485 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $45.00, for a total transaction of $246,825.00. Following the completion of the sale, the senior vice president directly owned 46,756 shares of the company’s stock, valued at $2,104,020. This trade represents a 10.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Hedge Funds Weigh In On Ralliant
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. The Manufacturers Life Insurance Company boosted its holdings in shares of Ralliant by 57.8% in the 1st quarter. The Manufacturers Life Insurance Company now owns 181,407 shares of the company’s stock worth $7,545,000 after buying an additional 66,443 shares during the last quarter. Quantinno Capital Management LP boosted its holdings in shares of Ralliant by 15.1% in the 1st quarter. Quantinno Capital Management LP now owns 74,021 shares of the company’s stock worth $3,079,000 after buying an additional 9,714 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Ralliant in the 1st quarter worth about $3,593,000. Renaissance Technologies LLC boosted its holdings in shares of Ralliant by 28.6% in the 1st quarter. Renaissance Technologies LLC now owns 371,082 shares of the company’s stock worth $15,433,000 after buying an additional 82,580 shares during the last quarter. Finally, Gabelli Funds LLC boosted its holdings in shares of Ralliant by 28.2% in the 1st quarter. Gabelli Funds LLC now owns 38,257 shares of the company’s stock worth $1,591,000 after buying an additional 8,421 shares during the last quarter.
Ralliant Company Profile
Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.
The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.
Read More
- Five stocks we like better than Ralliant
- Robinhood, SoFi, and Webull Are Telling Very Different Stories
- As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants In
- Target the Red-Hot Spin-Off and Merger Space With These ETFs
- Samsung Joins the $1 Trillion Club as AI Memory Demand Explodes
Receive News & Ratings for Ralliant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ralliant and related companies with MarketBeat.com's FREE daily email newsletter.
